Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Allergy & Immunology
•
Allergic Rhinitis and Conjunctivitis
•
Primary Care
When do you consider lifelong AIT?
Related Questions
How do you manage recurrent epistaxis from nasal steroids?
Do you routinely take a cancer history from patients being evaluated for atopy?
Do you retest for environmental aeroallergens when patients have relocated within the US between vastly different climates?
How do you counsel parents about the anticipated abdominal pain associated with oral desensitization in peanut-allergic children?
Do you believe that pretreatment with montelukast or other LTRAs can reduce the risk of urticaria or angioedema with NSAIDS?
Which patient characteristics or scenarios drive you to choose tezepelumab over dupilumab for asthma?
What are your recommendations for managing perivascular dermatitis with eosinophils unresponsive to high-dose antihistamines, a prednisone taper, and topical steroids?
How do you reassure families that no allergy testing is needed for urticaria?
Do you use asthma or EoE dosing if initiating dupilumab in a patient who meets criteria for treatment for both disorders?
Do you continue shots when a patient transfers under your care and has been receiving less than effective doses of AIT, but insist they have been effective?
